WaveMan
WaveMan · Company
BCYC · Bicycle Therapeutics Plc
> Search tickers & screens ⌘K
LIVE
← All companies

BCYC Bicycle Therapeutics (BCYC) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001761612
Quote by TradingView
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
53
13F, latest reported quarter

What the filings say about BCYC

Insiders, 180 days
-$123.3K net sold
6 sellers · 17% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$31.2K
1 notice

Bicycle Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, BICYCLE THERAPEUTICS PLC insiders sold a net $123.3K of stock across 213 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Thompson Travis Alvin
Chief Financial Officer
SELL
2026-10-06 SECtraded 2026-10-05
79
$282
+1.3%
Context
  • 28 earlier Form 4 trades (code P or S) here by this insider (28 sales), the last on Oct 2, 2026.
  • The trade is 0.1% of the 64,449 shares held after it.
  • 5 other insiders sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Thompson Travis Alvin sold about $282 of BCYC on Oct 5, 2026; 5 other insiders sold within 30 days and 53 funds added in the latest 13F quarter.
Skynner Michael
CHIEF SCIENTIFIC OFFICER
SELL
2026-10-06 SECtraded 2026-10-05
503
$1.8K
+1.3%
Context
  • 23 earlier Form 4 trades (code P or S) here by this insider (23 sales), the last on Oct 2, 2026.
  • The trade is 0.3% of the 154,726 shares held after it.
  • 5 other insiders sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF SCIENTIFIC OFFICER Skynner Michael sold about $1.8K of BCYC on Oct 5, 2026; 5 other insiders sold within 30 days and 53 funds added in the latest 13F quarter.
Hannay Michael Charles Ferguson
CHIEF PROD & SUPPLY CHAIN OFF
SELL
2026-10-06 SECtraded 2026-10-05
242
$864
+1.3%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Oct 2, 2026.
  • The trade is 0.3% of the 92,561 shares held after it.
  • 5 other insiders sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguson sold about $864 of BCYC on Oct 5, 2026; 5 other insiders sold within 30 days and 53 funds added in the latest 13F quarter.
Perry Jennifer Scott
Chief Operating Officer
SELL
2026-10-06 SECtraded 2026-10-05
80
$285
+1.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Oct 2, 2026.
  • The trade is 0.1% of the 89,878 shares held after it.
  • 5 other insiders sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Perry Jennifer Scott sold about $285 of BCYC under a 10b5-1 plan on Oct 5, 2026; 5 other insiders sold within 30 days and 53 funds added in the latest 13F quarter.
Lee Kevin
CHIEF EXECUTIVE OFFICER
SELL
2026-10-06 SECtraded 2026-10-05
1,638
$5.8K
+1.3%
Context
  • 47 earlier Form 4 trades (code P or S) here by this insider (47 sales), the last on Oct 2, 2026.
  • The trade is 0.3% of the 595,866 shares held after it.
  • 5 other insiders sold within 30 days.
  • 53 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Lee Kevin sold about $5.8K of BCYC on Oct 5, 2026; 5 other insiders sold within 30 days and 53 funds added in the latest 13F quarter.
213 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 208 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$123.3K over 180 days
-$62.8K over 90 days
more than 54% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
53 funds bought in last quarter
below 52% of Pharma & Biotech
Revenue
+105.8% year over year
more than 84% of Pharma & Biotech
Margin
-301.7% net margin
below 72% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
42.6% of the float short (float per yahoo 2026-10-26) · 8.7 days to cover · settled 2026-09-30
more than 74% of Pharma & Biotech
What changed in the last 30 days
Oct 6CHIEF EXECUTIVE OFFICER Lee Kevin sold $27.2K (2 trades, Oct 2 to Oct 5)
Oct 6Director Swanton Robert Charles sold $11.9K (Oct 2)
Oct 6CHIEF SCIENTIFIC OFFICER Skynner Michael sold $8.5K (2 trades, Oct 2 to Oct 5)
Oct 6CHIEF PROD & SUPPLY CHAIN OFF Hannay Michael Charles Ferguson sold $6.3K (2 trades, Oct 2 to Oct 5)
Oct 2Officer Lee Kevin filed to sell $31.2K by Oct 2 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch BCYC

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-51.6%12M
-57%-34%-11%+12%2025-102025-122026-022026-042026-062026-082026-10 2026-01-05 · Lee Kevin sold $71.0K2026-01-02 · Lee Kevin sold $70.2K2026-04-02 · Lee Kevin sold $29.3K2026-07-02 · Lee Kevin sold $25.2K2026-01-02 · Young Alethia sold $22.4K2026-01-05 · Milnes Alistair sold $22.1K2026-01-02 · Milnes Alistair sold $22.1K2026-10-02 · Lee Kevin sold $21.4K2026-01-05 · Skynner Michael sold $21.1K2026-01-02 · Skynner Michael sold $20.7K2026-01-02 · Hannay Michael Charles Ferguson sold $19.2K2026-01-05 · Young Alethia sold $15.8K2026-01-05 · Hannay Michael Charles Ferguson sold $15.3K2026-01-05 · Young Alethia sold $12.3K2026-10-02 · Swanton Robert Charles sold $11.9K2026-04-02 · Skynner Michael sold $9.2K2026-01-02 · Thompson Travis Alvin sold $9.0K2026-04-06 · Lee Kevin sold $8.7K2026-07-02 · Skynner Michael sold $7.9K2026-07-06 · Lee Kevin sold $7.5K2026-04-02 · Hannay Michael Charles Ferguson sold $7.5K2026-01-05 · Thompson Travis Alvin sold $7.2K2026-10-02 · Skynner Michael sold $6.7K2026-07-02 · Hannay Michael Charles Ferguson sold $6.4K2026-10-05 · Lee Kevin sold $5.8K2026-10-02 · Hannay Michael Charles Ferguson sold $5.5K2026-04-02 · Perry Jennifer Scott sold $5.1K2026-07-02 · Perry Jennifer Scott sold $4.4K2026-04-02 · Thompson Travis Alvin sold $3.9K2026-10-02 · Perry Jennifer Scott sold $3.8K2026-07-02 · Thompson Travis Alvin sold $3.5K2026-10-02 · Thompson Travis Alvin sold $3.1K2026-04-06 · Skynner Michael sold $2.7K2026-07-06 · Skynner Michael sold $2.3K2026-10-05 · Skynner Michael sold $1.8K2026-04-06 · Perry Jennifer Scott sold $1.7K2026-07-06 · Perry Jennifer Scott sold $1.4K2026-04-06 · Hannay Michael Charles Ferguson sold $1.3K2026-10-05 · Perry Jennifer Scott sold $1.2K2026-07-06 · Hannay Michael Charles Ferguson sold $1.1K2026-10-05 · Hannay Michael Charles Ferguson sold $8642026-04-06 · Thompson Travis Alvin sold $5152026-10-02 · Lee Kevin filed to sell $31.2K2026-07-02 · Lee Kevin filed to sell $34.2K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns BCYC: institutional holders (13F)

13F holdings, latest reported quarter
BAKER BROS. ADVISORS LP
10,885,357 sh
$46.2M
FCPM III SERVICES B.V.
3,468,430 sh
$14.7M
ARMISTICE CAPITAL, LLC
3,398,000 sh
$14.4M
Long Focus Capital Management, LLC
3,310,687 sh
$14.0M
RENAISSANCE TECHNOLOGIES LLC
1,533,400 sh
$6.5M

Congress trades in BCYC

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

BCYC planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Lee Kevin
Filed 2026-10-02
$31.2K
Lee Kevin
Filed 2026-07-02
$34.2K

BCYC mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Virtus Biotech Clinical Trials Etf
$296.2K position · as of 2026-07-31
0.6%
Invesco NASDAQ Future Gen 200 ETF
$62.9K position · as of 2026-05-31
0.3%
Horizon Kinetics Medical ETF
$53.4K position · as of 2026-06-30
0.3%
ALPS Medical Breakthroughs ETF
$241.3K position · as of 2026-05-31
0.1%
Health Sciences Trust
$108.6K position · as of 2026-06-30
0.0%
T. Rowe Price Health Sciences Portfolio
$266.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$6.3M
$1.9M
$2.3M
-76%
n/a
2024
$4.9M
$3.3M
$2.3M
-53%
n/a
2023
$5.5M
$625.1K
$2.8M
-39%
n/a
2022
$8.6M
-$6.4M
$4.0M
+65%
-11%
2021
$4.5M
$25.7M
$1.7M
+239%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $123.3K sold by insiders over 180 days, 53 funds added last quarter, $31.2K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

BCYC financials

Revenue growth
+105.8%
XBRL, annual
Net margin
-301.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$61.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-311.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$208.3M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.06x
long-term 2024-06-30 (24 months older than the period end) plus current 2024-06-30 (24 months older than the period end); equity 2026-06-30
Cash flow to debt
-6.67x
TTM operating cash flow over long-term 2024-06-30 (24 months older than the period end) plus current 2024-06-30 (24 months older than the period end)
Return on equity
-32.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-26.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-32.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
-$365.6M
market value at close 2026-10-27 on 2023-05-01 shares, plus long-term 2024-06-30 (24 months older than the period end) plus current 2024-06-30 (24 months older than the period end), minus cash 2026-06-30
FCF yield
-183.4%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$72.6M$35.3M$27.0M$14.5M
Operating income-$247.1M-$209.9M-$189.9M-$116.7M
Net income-$219.0M-$169.0M-$180.7M-$112.7M
EPS (diluted)-3.16-2.90-5.08-3.80
Operating cash flow-$249.7M-$164.7M-$60.6M-$86.1M
Cash$628.1M$879.5M$526.4M$339.2M
Long-term debtn/an/a$30.7M$30.3M
SEC XBRL, fiscal years, as known on 2026-10-28

BCYC Stock Sonar score 6/7 axes

Find similar shapesCompare

BCYC ranks highest on growth (84th percentile) and profitability (65th), and lowest on risk and compliance (1st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
65
Inputs
  • Return on equity-32.3% · 66 pct, sector of 545
  • Return on assets-26.5% · 63 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-32.0% · 66 pct, sector of 576
Financial health
43
Inputs
  • Debt to equity0.06x · 60 pct, sector of 352
  • Cash flow to debt-6.67x · 27 pct, sector of 371
Growth
84
Inputs
  • Revenue growth, YoY+105.8% · 84 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
26
Inputs
  • Net Form 4 buying (codes P and S), 180d-$118K · 53 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
52
Inputs
  • Funds adding, latest quarter53 · 48 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$300K · 57 pct, sector of 133
Risk and compliance
1
Inputs
  • Short interest, % of float+42.6% · 1 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

BCYC filings, in plain words

Are Bicycle Therapeutics insiders buying or selling BCYC?

In the 180 days to 2026-10-28, Bicycle Therapeutics insiders were net sellers, a net $123.3K across purchases and sales reported on Form 4, by 6 sellers.

Are there planned insider sales of BCYC?

Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $31.2K of stock; the latest, by Lee Kevin, was filed 2026-10-02.

Read the full summary

In the 180 days to 2026-10-28, Bicycle Therapeutics insiders were net sellers of BCYC, a net $123.3K across purchases and sales reported on Form 4 by 6 sellers. 17% of the 24 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $31.2K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies